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Purpose: Peroxisome proliferator-activated receptor (PPAR)-γ ligand is known to repress the 
expression of pro-inflammatory mediators. However, it is unclear how it affects PPAR-γ expression and 
the inflammatory response in the human lung. We investigated the effects of rosiglitazone (synthetic 
PPAR-γ ligand) on the PPAR-γ expression and on the IL-6 and IL-8 production in acute lung injury 
model using human lung epithelial cells.  
Methods: A549 and Beas-2B cells were pre-treated with rosiglitazone and/or BADGE (selective PPAR-
γ antagonist) and then treated with media control or cytokine mixture including TNF-α, IL-1β, and IFN-γ. 
PPAR-γ expression was analyzed in cell lysates by Western blot. IL-6 and IL-8 production was 
measured in the culture supernatants by ELISA.  
Results: PPAR-γ expression was identified in all experimental groups except for the control. The 
cytokine mixture-induced IL-6 and IL-8 production was significantly inhibited by pre-treatment with 
rosiglitazone (P<0.01). However, this inhibitory effect of rosiglitazone was not reversed by BADGE.  
Conclusion: These suggest that rosiglitazone induces the PPAR-γ expression and it may inhibit the 
cytokine mixture-induced IL-6 and IL-8 production through the PPAR-γ independent pathway. The 
inhibitory mechanisms of rosiglitazone on the cytokine mixture-induced IL-6 and IL-8 production in 
human alveolar and bronchial epithelial cells remain to be further investigated. 
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INTRODUCTION 
 
Various cytokines and inflammatory 
mediators participate in inflammatory 
response of acute lung injury (ALI). In the 
midst of them, interleukin (IL)-6 secreted from 
diverse cells in pulmonary tissue is involved 
in inflammatory response accompanied with 
tissue injury and IL-8 plays an important role 
in neutrophil infiltration into pulmonary tissue 
through its powerful chemotaxis to neutrophil 
[1]. In addition, although alveolar and 
bronchial epithelial cells are major target cells 
of inflammatory response of ALI, they can act 
as effector cells secreting IL-6 and IL-8. 
Therefore, these two cells are pivotal in the 
pathophysiology of ALI [2,3]. 
 
Peroxisome proliferator-activated receptor 
(PPAR) which belong to the nuclear hormone 
receptor superfamily is a transcription factor 
activated by ligand [4]. To date, three major 
types of PPAR, encoded by separate genes, 
have been identified; they are PPAR-α, 
PPAR-β/δ, and PPAR-γ. PPAR is 
ubiquitously expressed throughout the body. 
PPAR-α is expressed in numerous 
metabolically active tissues including liver, 
heart, kidney, and skeletal muscles, intestine, 
and pancreas and is also detectable in lung, 
placenta, and adipose tissues [5,6]. PPAR-γ 
is expressed mainly in adipose tissues and 
plays a role in differentiation of adipocytes 
[7]. PPAR-γ is also expressed in airway 
smooth muscles, airway epithelial cells, and 
alveolar macrophages [8,9]. On the other 
hand, PPAR-β/δ is expressed in most tissues 
and its action is not well known [5,10]. The 
PPARs regulate gene expression in 
heterodimeric association with retinoid X 
receptors (RXRs) to specific PPAR response 
elements in the promoter regions of specific 
target genes. It has been suggested that the 
functions of PPAR are restricted to lipid 
metabolism and maintenance of homeostasis 
[11]. But, recent studies reported that 
activation of PPAR controls not only cellular 
proliferation and activation but also 
inflammatory response [12]. It is now known 
that binding of ligand to PPAR-γ inhibits 
inflammatory genes by regulating another 
transcriptional factor, such as NF-κB (nuclear 
factor kappa B) [13].  
 
Since the finding that activation of PPAR-γ 
repressed the expression of inflammatory 
mediators [14], researches on the anti-
inflammatory effect of PPAR-γ increased. 
The studies on the anti-inflammatory effect of 
PPAR using thiazolidinedione (PPAR-γ 
ligand, TZD) as a drug that improves insulin 
resistance is actively in progress [15,16]. 
However, little is known about the anti-
inflammatory effect of PPAR from resident 
tissue cells, particularly human lung, in ALI 
model. Therefore, we sought to know if 
rosiglitazone (a synthetic PPAR-γ ligand) 
could induce the expression of PPAR-γ, and 
also whether it had effect on IL-6 and IL-8 
production, which are inflammatory mediators 
in ALI, when cells are stimulated by a 
cytokine mixture in human alveolar and 




Cell culture and preparation  
 
Human alveolar epithelial (A549) cells 
(Korean Cell Line Bank, Seoul, Korea) were 
cultured in RPMI 1640 (GIBCO) medium 
supplemented with L-glutamine (300 mg/L), 
10% FBS (JRH Biosciences, Lenexa, KS, 
USA), 20 mM HEPES (GIBCO, Carlsbad, 
CA, USA), sodium bicarbonate (2000 mg/L, 
GIBCO) and antibiotics (penicillin 100 U/ml, 
streptomycin 100 µg/ml, GIBCO). Human 
bronchial epithelial (Beas-2B) cells (American 
Type Culture Collection, Rockville, MD, USA) 
were cultured in DMEM/F12 (Sigma-Aldrich, 
St. Louis, MO, USA) medium supplemented 
with L-glutamine (365 mg/L), 10% FBS (JRH 
Biosciences, Lenexa, KS, USA), 15 mM 
HEPES (GIBCO, Carlsbad, CA, USA), 
sodium bicarbonate (1200 mg/L, GIBCO) and 
antibiotics (penicillin 100 U/ml, streptomycin 
100 µg/ml, GIBCO). 
 
To measure cell viability, 1×10
4 
cells/well 
were seeded in 96-well culture plate. To 
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examine the expression of PPAR-γ and IL-6 
and IL-8 production in A549 and Beas-2B 
cells, each cell was seeded in 6-well culture 
plate at a density of 2×10
5
 (A549) and 3×10
5
 
(Beas-2B) cells/well. These cell lines were 
cultured for 2 days, and then FBS 
concentration was reduced by twenty times 
from 10 to 0.5 %. The cells were treated with 
rosiglitazone (Alexis biochemicals, Plymouth 
Meeting, PA, USA) and bisphenol A diglycidyl 
ether (a selective PPAR-γ antagonist, 
BADGE, Sigma-Aldrich) at various 
concentrations for 1 h. After all the 
treatments, cytokine mixture [17] was added 
and after 24 h, the cells were collected. In all 
the experiments, the cells selected from the 
4th subculture were used. 
 
Supernatant was harvested and kept at -70 ℃ to measure IL-6 and IL-8 production. To 
examine the expression of PPAR-γ, the cell 
membranes were dissolved in lysis buffer [1 
% Triton X-100, 1 mM EGTA, 10 mM Tris (pH 
7.2), 1 mM Benzamidine, 1 mM Na3VO4, 158 
mM NaCl, 1% Sodium deoxycholate, and 0.1 
% SDS]. The collected cells were centrifuged 
at 13,000 rpm for 15 min. After the 
supernatant was discarded, the cells were 
kept at -20 ℃. 
 
Classification of experimental groups 
 
The experimental groups were classified as 
follows: control group, cytokine mixture 
treatment group (CM), rosiglitazone treatment 
group (RSG), the group of cytokine mixture 
treatment after pre-treatment with 
rosiglitazone (RSG+CM), and the group of 
cytokine mixture treatment after pre-
treatment with rosiglitazone and BADGE 
(RSG+BADGE+CM). The RSG+BADGE+CM 
group was subdivided into three groups 
according to the concentration of BADGE (5, 
25, and 50 µM) (Table 1). 
   
Measurement of cell viability 
 
Cell viability was determined with MTT assay 
using Cell Counting Kit-8 (Dojindo 
Laboratories, Tokyo, Japan). Briefly, the cells 
were seeded in 96-well plates and treated as 
mentioned above. The samples were 
analyzed by an ELISA plate reader at 450 nm 
wavelength. Cell viability of the experimental 
groups was indicated as relative percentage 
to the control group. 
 
Table 1: Classification of experimental groups 
 
Group 1 Control (medium only) 
Group 2   Medium 1hr + Cytokine mixture 24 h 
Group 3   Rosiglitazone 50 µM 1hr + Medium 24 
h 
Group 4 Rosiglitazone 50 µM 1hr + Cytokine 
mixture 24 h 
Group 5 (Rosiglitazone 50 µM + BADGE 5 µM) 
1 hr + Cytokine mixture 24 h 
Group 6 (Rosiglitazone 50 µM + BADGE 25 
µM) 1hr + Cytokine mixture 24 h 
Group 7 (Rosiglitazone 50 µM + BADGE 50 
µM) 1hr + Cytokine mixture 24 h 
BADGE: bisphenol A diglycidyl ether, Cytokine 
mixture: TNF-α (4 ng/ml) + IL-1β (1 ng/ml) + IFN-γ 
(10 ng/ml)  
 
Induction and inhibition of PPAR-γ 
expression 
 
Rosiglitazone of 50 µM was used to induce 
PPAR-γ expression. To inhibit the ability of 
rosiglitazone to stimulate transcriptional 
activity of PPAR-γ, BADGE of 5, 25, and 50 
µM was used. Rosiglitazone and BADGE 
were dissolved with DMSO (dimethyl-
sulfoxide, Sigma-Aldrich). Expression of 
PPAR-γ was measured by western blot 
analysis. 
 
Protein content was quantified by Bradford 
assay using Coomassie plus protein assay 
reagent (Pierce, Rockford, IL, USA). Total 
proteins taken from each sample were loaded 
on 8 % sodium dodecyl sulfate 
polyacrylamide gel and subjected to 
electrophoresis (SDS-PAGE). After 
electrophoresis, proteins were transferred 
onto a PVDF membrane (Amersham 
Pharmacia Biotech, Buckinghamshire, UK) 
and blocked with 10% skim milk for 15 
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minutes. The membrane was incubated 
overnight with a primary antibody for mouse 
anti-PPAR-γ monoclonal antibody (1:200, 
Santa Cruz Biotech, West Grove, PA, USA) 
at room temperature. 
 
After washing three times with PBS, the 
membrane was incubated with a secondary 
antibody, Donkey anti-mouse IgG-HRP 
(1:1000, Santa Cruz Biotech) for 30 minutes 
at room temperature. Protein was detected 
by chemiluminescence with the ECL Western 
Blotting Analysis System (Amersham 
Pharmacia Biotech, Buckinghamshire, UK). 
The hybridized membranes were exposed to 
X-ray film (Amersham Pharmacia). The band 
intensity of PPAR-γ was measured with a 
densitometer. The expressed PPAR-γ was 
indicated as relative percentage of β-actin 
(housekeeping protein). 
 
Induction and measurement of IL-6 and IL-
8 production 
 
Cytokine mixture (R&D systems, 
Minneapolis, MN, USA) [17] was used to 
induce IL-6 and IL-8 production. The 
concentration of each cytokine in the mixture 
was 4 ng/ml (TNF-α), 1 ng/ml (IL-1β), and 10 
ng/ml (IFN-γ). After incubation for 24 hours, 
supernatants were harvested. The 
supernatants were diluted as follows; 1:10 
and 1:50 for IL-6 from A549 and Beas-2B 
cells, 1:200 for IL-8 from A549 and Beas-2B 
cells. The supernatants concentration of IL-6 
and IL-8 was measured with Human ELISA 
set (BD biosciences Pharmingen, San Diego, 
CA, USA) following the manual. Lowest limit 
of measurement was 4.7 pg/ml for IL-6 and 
3.1 pg/ml for IL-8. The average concentration 
of IL-6 and IL-8 was 4.7~300 pg/ml and 
3.1~200 pg/ml, respectively. Optical density 




Statistical analysis was carried out by one-
way analysis of variance (ANOVA) with a 
Bonferroni post-hoc test using SPSS version 
12.0 for windows (SPSS Inc., Chicago, IL, 
USA). P < 0.05 was considered to indicate 
statistical significance. All values were 




There was no significant reduction in cell 
viability in all the experimental groups (Fig 1). 
Western blot analysis showed the expression 
of PPAR-γ in all experimental groups except 
for the control (Fig 2). 
 
 
Fig 1: Effects of rosiglitazone, BADGE, and 
cytokine mixture on cell viability of A549 and 
Beas-2B cells. Note: Data are mean ± S.E.M. from 
three independent experiments. RSG: 
rosiglitazone, BADGE: bisphenol A diglycidyl 
ether, CM: cytokine mixture. 
 
 
Fig 2: Expression of PPAR-γ in A549 and Beas-
2B cells. Note: Data are mean ± S.E.M. from three 
independent experiments. RSG: rosiglitazone, 
BADGE: bisphenol A diglycidyl ether, CM: cytokine 
mixture. * P<0.01 vs Control. 
 
There was no significant difference in the 
degree of expression of PPAR-γ between 
each experimental group except for the 
control. IL-6 and IL-8 production under 
stimulation with cytokine mixture was 
significantly increased compared with the 
control or rosiglitazone treatment (Figs 3 and 
4). The increase in IL-6 and IL-8 production 
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under stimulation with cytokine mixture was 
significantly decreased by pre-treatment with 
rosiglitazone. The rosiglitazone-mediated 
decrease of IL-6 and IL-8 production was not 
reversed by co-treatment with PPAR-γ 
antagonist, BADGE. All these findings were 
observed in both cell lines. 
 
Fig 3: Effects of rosigiltazone and BADGE on 
cytokine mixture-induced IL-6 production in A549 
and Beas-2B cells. Note: Data are mean ± S.E.M. 
from three independent experiments. RSG: 
rosiglitazone, BADGE: bisphenol A diglycidyl 
ether, CM: cytokine mixture. * P<0.01 vs Control 
or RSG, # P<0.01 vs CM.  
 
 
Fig 4: Effects of rosigiltazone and BADGE 
cytokine mixture-induced IL-8 production in A549 
and Beas-2B cells. Note: Data are mean ± S.E.M. 
from three independent experiments. RSG: 
rosiglitazone, BADGE: bisphenol A diglycidyl 
ether, CM: cytokine mixture. * P<0.01 vs Control 




ALI is a severe respiratory disease 
progressing to acute respiratory distress 
syndrome (ARDS) unless proper and early 
treatment is performed [2]. A characteristic 
view in the pathophysiologic mechanism of 
ALI is that it is a neutrophil-dependent lung 
injury. Numerous cytokines secreted from 
activated alveolar macrophages play a crucial 
role in the chemotaxis and activation of 
neutrophils, and various pro-inflammatory 
materials secreted from this activated 
neutrophils work in a complex way and 
participate in the lung injury [3,18,19]. 
Following recent interest in inflammatory 
cytokines secreted from activated 
neutrophils, several efforts to develop new 
drugs for ALI are ongoing. In particular, 
researches on anti-inflammatory effects using 
PPAR ligand have increased. 
 
Since it is known that PPAR has an important 
function in the control energy homeostasis 
and inflammatory response, some studies 
using various synthetic PPAR ligands have 
been reported. Many clinical investigations 
using these synthetic ligands including 
rosiglitazone, pioglitazone, and troglitazone, 
are under way. For example, Liu et al 
reported that rosiglitazone significantly 
reduced endotoxin-induced ALI in rats [20]. 
Also, Ito et al showed that pre-treatment with 
pioglitazone, a PPAR-γ agonist, before 
ischemia attenuated lung ischemia-
reperfusion injury in rats [21]. On the 
contrary, Inoue et al disclosed that 15-deoxy-
∆
12,14
-prostaglandin J2 (15d-PGJ2), a PPAR-γ 
ligand, did not improve but significantly 
enhanced ALI induced by lipopolysaccharide 
in the mouse [22]. 
  
In our study, we identified that rosiglitazone 
could directly induce the expression of 
PPAR-γ in alveolar and bronchial epithelial 
cells, resident tissue cells of lung. This finding 
is in agreement with the previous in vitro 
study [8, 9]. One interesting finding is that the 
cytokine mixture itself induced the expression 
of PPAR-γ in both cell lines. It may be 
associated with a part of the natural 
defensive mechanism against external insult.  
 
Regarding the effects on IL-6 and IL-8 
production, treatment with the cytokine 
mixture increased IL-6 and IL-8 production 
compared with the control group in both cell 
lines. The increase of IL-6 and IL-8 
production by treatment with the cytokine 
mixture was significantly decreased by pre-
treatment with rosiglitazone. However, when 
they were simultaneously treated with 
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rosiglitazone and BADGE, decrease of IL-6 
and IL-8 production by pre-treatment with 
rosiglitazone was not reversed. These results 
suggest that there may be a PPAR-γ 
independent pathway on anti-inflammatory 
effects of rosiglitazone in human alveolar and 
bronchial epithelial cells. In fact, there are 
several other reports in agreement with our 
results.  
 
Hinz et al delineated a PPAR-γ independent 
inhibitory action of 15d-PGJ2 on the 
expression of several pro-inflammatory genes 
in LPS-induced human blood monocytes, and 
also showed that it was not reversed by 
BADGE [23]. In addition, Chawla et al 
identified that the inhibitory ability of 15d-
PGJ2 and various TZDs on the pro-
inflammatory cytokines secreted from wild-
type macrophages treated with LPS was 
equally effective in PPAR-γ-deficient 
macrophages [24], emphasizing that the 
inhibitory effect of 15d-PGJ2 and various 
TZDs on inflammatory cytokine production 
may be receptor independent.  
 
Although these studies showed the PPAR-γ 
independent pathway of PPAR-γ ligand, few 
reports on PPAR-γ independent pathway of 
rosiglitazone in inflammatory models has 
been demonstrated until now. Seargent et al 
documented that the anticancer effect of 
rosiglitazone was not reversed by GW9662, a 
PPAR-γ antagonist, in brest tumor cells [25]. 
This means that the growth inhibition of tumor 
cells induced by rosiglitazone occurs 
independent of PPAR-γ activation. In 
addition, Derlacz et al reported PPAR-γ 
independent inhibitory effect of rosiglitazone 
on glucose synthesis in primary cultured 
rabbit kidney-cortex tubules [26]. Even if 
there were more studies suggesting PPAR-γ 
independent pathway of rosiglitazone, almost 
all the studies were performed in non-
inflammatory models. From this viewpoint, 
our study may be the first study implying 
PPAR-γ independent anti-inflammatory effect 
of rosiglitazone in resident tissue cells, 
particularly human lung. 
 
There were several studies suggesting a 
mechanism of PPAR-γ independent pathway 
of PPAR-γ ligand in detail. A change of 
intracellular pH concentration may explain a 
mechanism of PPAR-γ independent pathway 
[27]. Turturro et al that showed that 
troglitazone inhibited cellular proliferation 
through intracellular acidosis and blockage of 
DNA synthesis in breast cancer-derived cell 
lines. It was identified that troglitazone-
mediated inhibition of cellular proliferation 
was not reversed by the presence of the 
PPAR-γ inhibitor GW9662 and was 
demonstrable in PPAR-γ-deficient cells, 
consistent with a PPAR-γ independent 
mechanism. According to other recent 
studies, it has been reported that 
mitochondria play important role on the 
PPAR-γ independent pathway of PPAR-γ 
ligand.  
 
Pérez et al reported PPAR-γ independent 
cytotoxicity of ciglitazone in astrogial cells 
[28]. It suggests that the production of 
reactive oxygen species (ROS) and the rapid 
loss of mitochondrial membrane potential in 
astroglial cells may explain the PPAR-γ 
independent pathway on the cytotoxicity of 
ciglitazone. Therefore, they indicated that 
ROS had a key role in glitazone cytotoxity 
and the mitochondria were a likely source of 
ROS and early targets of it. Scatena et al 
reported that PPAR-γ ligands inhibited 
NADH-cytochrome c reductase activity and 
induced the derangement of mitochondrial 
respiratory chain from HP-60 (human acute 
promyelocytic leukemia) cell lines, suggesting 
a non-receptor-mediated effect of synthetic 
PPAR-ligands [29]. In addition, recent study 
has demonstrated a novel binding site 
(termed “mitoNEET”) of glitazones in 
mitochondria, using tritiated pioglitazone and 
a photoaffinity cross-linker [30].  
 
Although additional studies may be required, 
these reports mentioned above and the 
outcome of this study could raise the 
intriguing possibility that rosiglitazone may 
have another pathway, not PPAR-γ, in 
human pulmonary epithelial cells. 
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CONCLUSION 
 
Our in vitro investigation demonstrated that 
rosiglitazone, a PPAR-γ agonist, possesses 
anti-inflammatory properties in human 
pulmonary epithelial cells. This provides an 
evidence for the therapeutic potential of 
rosiglitazone in the treatment of ALI. Judging 
from the effect of BADGE on the anti-
inflammatory action of rosiglitazone, it is 
postulated that rosiglitazone could have an 
anti-inflammatory effect via a PPAR-γ 
independent pathway. However, further 
investigation will be needed to characterize 
the exact PPAR-γ independent pathway of 
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